结核病（TB）是全球重大公共卫生挑战之一。团队以临床问题为导向，针对结核病防治中的"卡脖子"问题，聚焦结核发病机制和诊治新技术，借助"国家感染性疾病临床医学研究中心"这一高端平台，整合资源，协同攻关，在结核病原创性研究中取得一定成绩，学术贡献如下：（1）阐明干扰素应答在结核免疫应答中的调控作用和机制；（2）鉴定多个结核易感基因及宿主定向治疗靶点，提出靶向"肺-肠轴"控制结核感染的理论并完成概念验证；（3）开发基于CRISPR和全基因测序的结核诊断技术，制定基于γδT细胞的结核病宿主定向治疗新策略。团队研究成果入选教育部、广东省、深圳市等各级奖励，为结核病的精准防控和个体化治疗提供重要理论依据和科学支撑。Tuberculosis (TB) is one of the major public health challenges. The team is guided by clinical issues and focuses on the "bottleneck" problems in TB. Under the platform of National Clinical Research Center for Infectious Diseases, it integrates resources and collaborates with partners to make innovative achievements in TB research. The academic contributions are as follows: (1) Clarify the regulatory roles and mechanism of interferon response in TB; (2) Identify multiple TB susceptible genes and host-directed therapy targets, propose the theory of targeting the "lung-intestine axis" to control TB and complete the proof of concept; (3) Develop TB diagnostic technology based on CRISPR and whole-genome sequencing, formulate a new cellular therapy strategy for TB using γδT cells. The research achievements were selected into awards at various levels such as the Ministry of Education, Guangdong Province, Shenzhen City, etc., providing important theoretical basis for the precise prevention and individualized treatment of TB.
